Session » Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 319

A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine

9:00AM-11:00AM: Abstract Number: 324

Adherence to Guideline Directed Management of Gout Among VA Providers

9:00AM-11:00AM: Abstract Number: 321

Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 307

ANA-lysis: Utility of Repeated Antinuclear Antibody Testing in a Single Center

9:00AM-11:00AM: Abstract Number: 326

Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?

9:00AM-11:00AM: Abstract Number: 323

Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients

9:00AM-11:00AM: Abstract Number: 311

Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 310

Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center

9:00AM-11:00AM: Abstract Number: 325

Frailty and Sarcopenia in Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 320

Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

9:00AM-11:00AM: Abstract Number: 322

Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population

9:00AM-11:00AM: Abstract Number: 316

Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA

9:00AM-11:00AM: Abstract Number: 317

Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative

9:00AM-11:00AM: Abstract Number: 318

Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 315

Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire

9:00AM-11:00AM: Abstract Number: 309

Increasing Capacity and Reducing Costs of Rituximab Administration

9:00AM-11:00AM: Abstract Number: 306

Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders

9:00AM-11:00AM: Abstract Number: 305

Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing

9:00AM-11:00AM: Abstract Number: 314

Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data

9:00AM-11:00AM: Abstract Number: 327

Presentation Order Bias in Rheumatology Journals: A Content Analysis

9:00AM-11:00AM: Abstract Number: 308

Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays

9:00AM-11:00AM: Abstract Number: 313

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

9:00AM-11:00AM: Abstract Number: 304

The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017

9:00AM-11:00AM: Abstract Number: 312

Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].